Mark Erlander, Cardiff Oncology CEO
September 14, 2022 11:33 AM EDTUpdated September 16, 05:19 PM
R&D

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Aayushi Pratap

News Reporter

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times